Phreesia (PHR) Insider Lisa Egbuonu-Davis Buys $185K of Stock
Lisa Egbuonu-Davis bought 19,290 shares of Phreesia, Inc., totaling nearly $185,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lisa Egbuonu-Davis bought 19,290 shares of Phreesia, Inc. ($PHR) at an average price of $9.59, worth about $184,991.10, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PHR is up 11.8% after 1 week, up 6.6% after 1 month and up 14.1% to date (from the $9.59 close on Jun 24, 2026).
PHR
Phreesia, Inc.
Key Points
- On June 24, 2026, Lisa Egbuonu-Davis bought 19,290 shares of Phreesia, Inc. at $9.59 each, amounting to about $185,000.
- Phreesia's stock is currently trading around $9.13, which is below its 50-day moving average of $11.15.
- Analysts have mixed views on the stock, with a consensus target price of $13.94 from 16 analysts.
Get $PHR trade alerts by text
We text you when insiders, Congress or big funds trade $PHR. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Phreesia, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Phreesia, Inc.
On June 24, 2026, Lisa Egbuonu-Davis purchased 19,290 shares of Phreesia, Inc. (NYSE: PHR) for $9.59 each, totaling approximately $185,000. This transaction reflects her confidence in the company, which specializes in healthcare software solutions.
Other Insiders Join the Trend
Egbuonu-Davis wasn't alone in her buying activity on this date. Several other insiders also made similar purchases, including Jon Kessler, Gillian Munson, Ramin Sayar, Smith Mark Douglas, and Lainie Goldstein, each acquiring 19,290 shares at the same price of $9.59. This coordinated buying among insiders may suggest a strong belief in the company's future prospects.
Stock Performance and Market Context
Phreesia's stock is currently trading around $9.13, which is below its 50-day moving average of $11.15. The shares have seen a 52-week low of $7.77 and a high of $25.00, indicating considerable volatility. The recent insider purchases may be viewed as a positive signal amid this fluctuating stock performance.
Analysts Set New Price Targets
Analysts have mixed opinions on Phreesia. On October 12, 2026, Barclays maintained an Equal-Weight rating with a price target of $11.00. Meanwhile, Raymond James downgraded its rating to Market Perform on September 8, 2026. DA Davidson continues to rate the stock as a Buy, with a target of $13.00, while Canaccord Genuity maintains a Buy rating with a target of $16.00. The consensus among 16 analysts sets a mean price target of $13.94.
What PHR Does
Phreesia, Inc. provides a software platform that helps healthcare organizations manage patient intake, payments, and communications. This focus on improving healthcare workflows may be crucial as the industry continues to evolve, especially with the integration of AI technologies.
What's Ahead for PHR
Investors will be watching for Phreesia's next earnings report scheduled for December 7, 2026. As a reminder, insider transactions like this reflect past activity and may not indicate future stock performance. The recent purchases by multiple insiders may provide insights into their confidence in the company's growth trajectory.
Related Filing Alerts
Source: Lisa Egbuonu-Davis's Form 4 filing on $PHR (Jun 24, 2026). Find the original filing: PHR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts